

PATENT  
PC9808A

16148

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: K. M. Lundy  
et al.

APPLICATION NO.: 09/308,955

Examiner: C. Delacroix-  
Muirheid

FILING DATE: May 27, 1999

Group Art Unit: 1614

TITLE: Cox-2 Selective Carprofen for  
Treating Pain and Inflammation  
in DogsCommissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

Transmitted herewith is a response in the above-identified  
application.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2) Claims Remaining After Amendment	(3)	(4) Highest Number Previously Paid for	(5) Present Extra	(6) Rate	Addl Fee
Total Claims	14*	minus	20 **	= 0	X\$22.00	0
Independent Claims	3*	minus	3***	= 0	X\$80.00	0

Multiple Dependent Claim(s) Fee (\$260.00) 0

Total Additional Fee for this Amendment 0

\* If the entry in column 2 is less than the entry in  
column 4, write "0" in column 5.\*\* If the "Highest No. Previously Paid for" is less than  
20, write "20" in this space.\*\*\* If the "Highest No. Previously Paid for" is less than 3,  
write "3" in this space.RECEIVED  
MAR 28 2001  
TECH CENTER 1600/2900

☒ A Petition for Extension of Time for responding within one (1) months of the response date is also enclosed.

☒ No additional fee is required.

☐ Please charge Deposit Account No. 16-1445 in the amount of \_\_\_\_\_. Two copies of this sheet are enclosed.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.16 and 1.17, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this sheet are enclosed.

Respectfully submitted,

March 14, 2001  
(Date)

Grover F. Fuller Jr.  
GROVER F. FULLER JR.  
ATTORNEY for Applicants  
Reg. No. 31,760

Pfizer Inc.  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 573-1390



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant  
Commissioner for Patents, Washington, D.C. 20231 on this 14th day of March, 2001

By

*Grover F. Fuller Jr.*

(Signature of person mailing)  
Grover F. Fuller Jr.

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: K. M. Lundy *et al.* :

APPLICATION NO.: 09/308,955

: Examiner: C. Delacroix-Muirheid

FILING DATE: May 27, 1999

: Group Art Unit: 1614

TITLE: Cox-2 Selective Carprofen for Treating Pain  
and Inflammation in Dogs :

Commissioner of Patents and Trademarks  
Washington, D.C. 20231  
Sir:

#8  
JRP  
3/29/01

RESPONSE

This is a response to Official Action of January 17, 2001.

The claims are 1 to 14 and reconsideration is respectfully requested.

The examiner requested a more specific response to the term "therapeutically active agent" relevant to the election of species in claims 4 and 11.

Applicants, first of all, hereby incorporate all arguments and statements included in their response of November 6, 2000. In that response, Applicants elected the therapy of subparagraph "B" with respect to these claims. In response to the pending Action, Applicants furthermore hereby elect NSAIDs with traverse.

Applicants respectfully request that the claims be allowed and the Application passed on to issue.

Date:

*March 14, 2001*

Respectfully submitted,

*Grover F. Fuller Jr.*

Grover F. Fuller Jr.

Attorney for Applicant(s)

Reg. No. 31,760

Pfizer Inc  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 573-1390

RECEIVED  
MAR 28 2001  
TECH CENTER 1600/2900